NCT00393822View on ClinicalTrials.gov

A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

December 31, 2007

Study Completion Date

March 31, 2014

Conditions

Colon Cancer

Interventions

DRUG

palifermin

dose of 120 μg/kg, intravenous (IV) on day -3 for each cycle, for up to 6 chemotherapy cycles

DRUG

placebo

one bolus IV injection at 120 μg/kg/day of matched placebo

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Amgen

INDUSTRY